JP2005527618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527618A5 JP2005527618A5 JP2004507422A JP2004507422A JP2005527618A5 JP 2005527618 A5 JP2005527618 A5 JP 2005527618A5 JP 2004507422 A JP2004507422 A JP 2004507422A JP 2004507422 A JP2004507422 A JP 2004507422A JP 2005527618 A5 JP2005527618 A5 JP 2005527618A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- phenyl
- compound
- hydrogen
- ethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- ISUCIWOZCLTYCZ-DQEYMECFSA-N 4-[(1r)-1-hydroxy-2-[2-[4-[(2r)-2-hydroxy-2-(2-methoxyphenyl)ethoxy]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol Chemical compound COC1=CC=CC=C1[C@@H](O)COC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C(CO)=C1 ISUCIWOZCLTYCZ-DQEYMECFSA-N 0.000 claims 1
- VBMYBJFEOATURT-DQEYMECFSA-N 4-[(1r)-1-hydroxy-2-[2-[4-[(2r)-2-hydroxy-2-phenylethoxy]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 VBMYBJFEOATURT-DQEYMECFSA-N 0.000 claims 1
- UKDYESAQRFBPBI-DQEYMECFSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[(2r)-2-hydroxy-2-(2-methoxyphenyl)ethoxy]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound COC1=CC=CC=C1[C@@H](O)COC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 UKDYESAQRFBPBI-DQEYMECFSA-N 0.000 claims 1
- VFZJHRTZDUWGJN-DQEYMECFSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[(2r)-2-hydroxy-2-phenylethoxy]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C1([C@@H](O)COC2=CC=C(C=C2)CCNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=CC=C1 VFZJHRTZDUWGJN-DQEYMECFSA-N 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- LOCKTDWTJWSZHK-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[(2r)-2-hydroxy-2-(2-methoxyphenyl)ethoxy]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound COC1=CC=CC=C1[C@@H](O)COC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C(NC=O)=C1 LOCKTDWTJWSZHK-DQEYMECFSA-N 0.000 claims 1
- BQYRZGVILVMXRG-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[(2r)-2-hydroxy-2-phenylethoxy]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)COC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BQYRZGVILVMXRG-DQEYMECFSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38374702P | 2002-05-28 | 2002-05-28 | |
| PCT/US2003/016549 WO2003099764A1 (en) | 2002-05-28 | 2003-05-27 | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527618A JP2005527618A (ja) | 2005-09-15 |
| JP2005527618A5 true JP2005527618A5 (enExample) | 2006-07-13 |
Family
ID=29584596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004507422A Pending JP2005527618A (ja) | 2002-05-28 | 2003-05-27 | アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6747043B2 (enExample) |
| EP (1) | EP1507754A1 (enExample) |
| JP (1) | JP2005527618A (enExample) |
| AU (1) | AU2003239880A1 (enExample) |
| WO (1) | WO2003099764A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| US7317102B2 (en) * | 2003-04-01 | 2008-01-08 | Theravance, Inc. | Diarylmethyl and related compounds |
| EP1626970B1 (en) * | 2003-05-28 | 2009-07-08 | Theravance, Inc. | Azabicycloalkane compounds as muscarinic receptor antagonists |
| GB0316341D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| EP1643974A1 (en) * | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Inhalable pharmaceutical formulations comprising a sugar ester |
| US20060210485A1 (en) * | 2003-07-11 | 2006-09-21 | Marian Thomas | Pharmaceutical formulations |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| GB0324918D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2005080324A1 (en) * | 2004-01-22 | 2005-09-01 | Pfizer Limited | Sulfonamide derivatives for the treatment of diseases |
| KR100794844B1 (ko) * | 2004-01-22 | 2008-01-15 | 화이자 인코포레이티드 | 질병 치료용 설폰아마이드 유도체 |
| ATE375977T1 (de) * | 2004-01-22 | 2007-11-15 | Pfizer | Sulfonamidderivate zur behandlung von krankheiten |
| BRPI0507877A (pt) * | 2004-03-23 | 2007-07-24 | Pfizer | derivados de formamida, composição farmacêutica, uso dos mesmos e combinação |
| GB0425054D0 (en) * | 2004-03-23 | 2004-12-15 | Pfizer Ltd | Formamide derivatives for the treatment of diseases |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| CN1984876A (zh) * | 2004-06-03 | 2007-06-20 | 施万制药 | 二胺类β2肾上腺素能受体激动剂 |
| WO2006023457A1 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| JP2008510015A (ja) * | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| US8653145B2 (en) * | 2005-09-22 | 2014-02-18 | Eaton Scientific Systems, Ltd. | Method for alleviating climacteric symptoms |
| CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| PE20080361A1 (es) | 2006-04-21 | 2008-06-03 | Novartis Ag | Compuestos derivados de purina como activadores del receptor de adenosina a2a |
| ES2296516B1 (es) * | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| CN103739503A (zh) * | 2006-08-10 | 2014-04-23 | 美国政府健康及人类服务部 | (r,r)-非诺特罗和(r,r)-或(r,s)-非诺特罗类似物的制备及其在治疗充血性心力衰竭中的应用 |
| ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| EP2279777A2 (en) | 2007-01-10 | 2011-02-02 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| BRPI0807806A2 (pt) * | 2007-01-25 | 2014-06-17 | Boehringer Ingelheim Int | " processo para a fabricação de beta-miméticos ". |
| EA200901082A1 (ru) | 2007-02-09 | 2010-02-26 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| AU2008248598B2 (en) | 2007-05-07 | 2011-11-17 | Novartis Ag | Organic compounds |
| ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| CN101939054B (zh) | 2007-12-10 | 2014-10-29 | 诺华股份有限公司 | 有机化合物 |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| ES2535736T3 (es) | 2008-06-10 | 2015-05-14 | Novartis Ag | Derivados de pirazina como bloqueadores de los canales de sodio epitelial |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| PL2379507T3 (pl) | 2008-12-30 | 2014-03-31 | Pulmagen Therapeutics Inflammation Ltd | Związki sulfonamidu do leczenia zaburzeń układu oddechowego |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| MX2012004792A (es) | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US9492405B2 (en) | 2010-03-10 | 2016-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8394829B2 (en) * | 2010-05-10 | 2013-03-12 | Gilead Sciences, Inc. | Bi-functional quinoline analogs |
| WO2012032546A2 (en) * | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
| WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| KR20220019015A (ko) | 2019-06-10 | 2022-02-15 | 노파르티스 아게 | Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체 |
| AU2020338971B2 (en) | 2019-08-28 | 2023-11-23 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1250450B (de) | 1962-03-31 | 1967-09-21 | Deutsche Gold- und Silber-Scheideanstalt vormals Roessler, Frankfurt/M | Verfahren zur Herstellung von Aminoalkoholen sowie deren Säureadditionssalzen und quartären Ammoniumverbindungen |
| AT310146B (de) | 1971-04-26 | 1973-09-25 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen |
| BE786713A (fr) * | 1971-07-27 | 1973-01-25 | Sandoz Sa | Nouveaux amino-alcools, leur preparation et leur application comme medicaments |
| CH545764A (enExample) | 1971-07-27 | 1974-02-15 | ||
| BE794414A (fr) | 1972-01-25 | 1973-07-23 | Sandoz Sa | Nouveaux amino-alcools, leur preparation et leur application comme medicament |
| JPS609713B2 (ja) | 1976-10-08 | 1985-03-12 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| EP0070134B1 (en) | 1981-07-11 | 1985-11-13 | Beecham Group Plc | Secondary phenyl ethanol amines and their pharmaceutical use |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GB8507942D0 (en) | 1985-03-27 | 1985-05-01 | Beecham Group Plc | Compounds |
| DK9987A (da) | 1986-01-11 | 1987-07-12 | Beecham Group Plc | Ethanolaminderivater |
| US4894219A (en) | 1988-03-29 | 1990-01-16 | University Of Florida | Beta-agonist carbostyril derivatives, assay method and pharmacological composition |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| PT938467E (pt) * | 1996-11-11 | 2002-11-29 | Sepracor Inc | Processo para a preparacao de isomeros opticamente puros de formoterol |
| JPH10152460A (ja) | 1996-11-21 | 1998-06-09 | Kissei Pharmaceut Co Ltd | ２−アミノ−１−（４−ヒドロキシ−２−メチルフェニル）プロパノール誘導体 |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6436914B1 (en) | 1998-06-30 | 2002-08-20 | Bristol-Myers Squibb Company | 2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1370521B1 (en) | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
| PL211953B1 (pl) | 2001-09-14 | 2012-07-31 | Glaxo Group Ltd | Pochodna fenetanoloaminy, zawierający ją środek farmaceutyczny i zastosowanie pochodnej fenetanoloaminy |
-
2003
- 2003-05-27 JP JP2004507422A patent/JP2005527618A/ja active Pending
- 2003-05-27 US US10/445,643 patent/US6747043B2/en not_active Expired - Lifetime
- 2003-05-27 EP EP03734187A patent/EP1507754A1/en not_active Withdrawn
- 2003-05-27 AU AU2003239880A patent/AU2003239880A1/en not_active Abandoned
- 2003-05-27 WO PCT/US2003/016549 patent/WO2003099764A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527618A5 (enExample) | ||
| JP2008507532A5 (enExample) | ||
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| JP2005533860A5 (enExample) | ||
| JP2008501705A5 (enExample) | ||
| RU2009118825A (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1ГИДРОКСИЭТИЛ)ФЕНОЛА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| US7439397B2 (en) | Phenol derivative | |
| RU2005140652A (ru) | Кристаллическая форма агониста бетта2-адренергического рецептора | |
| JP2005509024A5 (enExample) | ||
| ZA200608123B (en) | Combinations of glycopyrrolate and beta2 adrenoceptor agonists | |
| US7005449B2 (en) | Tolterodine salts | |
| RU2010139571A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола в качестве агонистов b2-адренергического рецептора | |
| JP2004507465A5 (enExample) | ||
| JP2004533450A5 (enExample) | ||
| JP2007518738A5 (enExample) | ||
| JP2011517316A5 (enExample) | ||
| JP2012518019A5 (enExample) | ||
| JP2005532397A5 (enExample) | ||
| JP2012518019A (ja) | 肺機能の処置のための、５−（２−｛［６−（２，２−ジフルオロ−２−フェニルエトキシ）ヘキシル］アミノ｝−１−ヒドロキシエチル）−８−ヒドロキシキノリン−２（１ｈ）−オン | |
| JP2006504768A (ja) | 四級アンモニウム化合物 | |
| JP2007524699A5 (enExample) | ||
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы | |
| JP2004514709A5 (enExample) | ||
| MXPA05003105A (es) | Compuestos de amonio cuaternario. | |
| JP2005529110A5 (enExample) |